Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy SummitGlobeNewsWire • 05/19/23
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.GlobeNewsWire • 05/17/23
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual MeetingGlobeNewsWire • 05/08/23
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate UpdateGlobeNewsWire • 04/27/23
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/27/23
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?Zacks Investment Research • 04/18/23
Ultragenyx to Present at Guggenheim's Genomic Medicines and Rare Disease DaysGlobeNewsWire • 03/28/23
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice PresidentGlobeNewsWire • 03/14/23
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare ConferenceGlobeNewsWire • 02/28/23
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate UpdateGlobeNewsWire • 02/16/23
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate UpdateGlobeNewsWire • 02/09/23
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/02/23
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 MilestonesGlobeNewsWire • 01/06/23